Umbilical cord-derived CD362+ mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy

Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source....

Full description

Saved in:
Bibliographic Details
Published inStem cell research & therapy Vol. 11; no. 1; pp. 116 - 11
Main Authors Horie, Shahd, Masterson, Claire, Brady, Jack, Loftus, Paul, Horan, Emma, O’Flynn, Lisa, Elliman, Steve, Barry, Frank, O’Brien, Timothy, Laffey, John G., O’Toole, Daniel
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 13.03.2020
BioMed Central
BMC
Subjects
Adult respiratory distress syndrome
Analysis
Antibiotics
ARDS
Bone marrow
Cell therapy
Cryopreservation
E coli
Escherichia coli
Infection
Isolation
Mesenchymal stem cell
Mesenchymal stem cells
Mesenchyme
Ostomy
Passage
Pneumonia
Production management
Respiratory distress syndrome
Setting (Literature)
Stem cells
Stromal cells
Time
Umbilical cord
Ventilators
United Kingdom
United Kingdom > UK
Ireland
Mesenchymal stem cell
Pneumonia
Antibiotics
Passage
Cryopreservation
ARDS
Online AccessGet full text

Cover

Abstract Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored. Adult male rats were subject to E. coli-induced pneumonia and administered CD362 umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362 UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362 UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation. CD362 UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362 UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362 UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation. These translational studies demonstrated the efficacy of CD362 UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury.
AbstractList Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored. Adult male rats were subject to E. coli-induced pneumonia and administered CD362.sup.+ umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362.sup.+ UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362.sup.+ UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation. CD362.sup.+ UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362.sup.+ UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362.sup.+ UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation. These translational studies demonstrated the efficacy of CD362.sup.+ UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury.
Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored.BACKGROUNDMesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored.Adult male rats were subject to E. coli-induced pneumonia and administered CD362+ umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362+ UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362+ UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation.METHODSAdult male rats were subject to E. coli-induced pneumonia and administered CD362+ umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362+ UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362+ UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation.CD362+ UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362+ UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362+ UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation.RESULTSCD362+ UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362+ UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362+ UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation.These translational studies demonstrated the efficacy of CD362+ UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury.CONCLUSIONSThese translational studies demonstrated the efficacy of CD362+ UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury.
Background Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored. Methods Adult male rats were subject to E. coli-induced pneumonia and administered CD362.sup.+ umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362.sup.+ UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362.sup.+ UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation. Results CD362.sup.+ UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362.sup.+ UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362.sup.+ UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation. Conclusions These translational studies demonstrated the efficacy of CD362.sup.+ UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury. Keywords: Mesenchymal stem cell, ARDS, Pneumonia, Cryopreservation, Passage, Antibiotics
Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored. Adult male rats were subject to E. coli-induced pneumonia and administered CD362 umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362 UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362 UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation. CD362 UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362 UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362 UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation. These translational studies demonstrated the efficacy of CD362 UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury.
Abstract Background Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored. Methods Adult male rats were subject to E. coli-induced pneumonia and administered CD362+ umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362+ UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362+ UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation. Results CD362+ UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362+ UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362+ UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation. Conclusions These translational studies demonstrated the efficacy of CD362+ UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury.
Background Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to MSC isolation generate highly heterogeneous cell populations, while bone marrow (BM) constitutes a limited and difficult to access MSC source. Furthermore, a range of cell manufacturing considerations and clinical setting practicalities remain to be explored. Methods Adult male rats were subject to E. coli-induced pneumonia and administered CD362+ umbilical cord (UC)-hMSCs using a variety of cell production and clinical relevance considerations. In series 1, animals were instilled with E. coli and randomized to receive heterogeneous BM or UC-hMSCs or CD362+ UC-hMSCs. Subsequent series examined the impact of concomitant antibiotic therapy, MSC therapeutic cryopreservation (cryopreserved vs fresh CD362+ UC-hMSCs), impact of cell passage on efficacy (passages 3 vs 5 vs 7 vs 10), and delay of administration of cell therapy (0 h vs 6 h post-injury vs 6 h + 12 h) following E. coli installation. Results CD362+ UC-hMSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. Cryopreserved CD362+ UC-hMSCs recapitulated this efficacy, attenuating E. coli-induced injury, but therapeutic relevance did not extend beyond passage 3 for all indices. CD362+ UC-hMSCs maintained efficacy in the presence of antibiotic therapy and rescued the animal from E. coli injury when delivered at 6 h + 12 h, following E. coli instillation. Conclusions These translational studies demonstrated the efficacy of CD362+ UC-hMSCs, where they decreased the severity of E. coli-induced pneumonia, maintained efficacy following cryopreservation, were more effective at early passage, were effective in the presence of antibiotic therapy, and could continue to provide benefit at later time points following E. coli injury.
ArticleNumber 116
Audience Academic
Author Horie, Shahd
Brady, Jack
Horan, Emma
O’Flynn, Lisa
Barry, Frank
O’Brien, Timothy
Laffey, John G.
Loftus, Paul
Masterson, Claire
O’Toole, Daniel
Elliman, Steve
Author_xml – sequence: 1
  givenname: Shahd
  surname: Horie
  fullname: Horie, Shahd
– sequence: 2
  givenname: Claire
  surname: Masterson
  fullname: Masterson, Claire
– sequence: 3
  givenname: Jack
  surname: Brady
  fullname: Brady, Jack
– sequence: 4
  givenname: Paul
  surname: Loftus
  fullname: Loftus, Paul
– sequence: 5
  givenname: Emma
  surname: Horan
  fullname: Horan, Emma
– sequence: 6
  givenname: Lisa
  surname: O’Flynn
  fullname: O’Flynn, Lisa
– sequence: 7
  givenname: Steve
  surname: Elliman
  fullname: Elliman, Steve
– sequence: 8
  givenname: Frank
  surname: Barry
  fullname: Barry, Frank
– sequence: 9
  givenname: Timothy
  surname: O’Brien
  fullname: O’Brien, Timothy
– sequence: 10
  givenname: John G.
  surname: Laffey
  fullname: Laffey, John G.
– sequence: 11
  givenname: Daniel
  surname: O’Toole
  fullname: O’Toole, Daniel
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32169108$$D View this record in MEDLINE/PubMed
BookMark eNp9k29r1TAUxotM3Jz7Ar6QgiCK68y_m6S-EMacOhgI6l6HNDm9N6NtuiQd3m_ixzXdnXN3iA0lIef3PGlOz3la7Ax-gKJ4jtERxpK_i5gSKSpEUIUwJ6ySj4o9LBai4gtMdu6td4uDGC9RfihFiLMnxS4lmNcYyb3i10XfuM4Z3ZXGB1tZCO4abHnykXLytuwhwmBW6z7HYwp-ng10XSxbH8rToyzqXDkOMPV-cPp96fpRm1T6trQ-Qhlg6XoYDstRx6iXcFiasPZjyLbhWifnc0gPNr_JNc4nZ8q0gqDH9bPicau7CAe3835x8en0x8mX6vzr57OT4_PKcCJTZRiVlGsr29YwqQWthSGtZgLbxkKzWJi2BsJ4CwxDTTEhukEtNGAQWTAh6X5xtvG1Xl-qMbheh7Xy2qmbDR-WSof8XR0oawUxRkpohGZM1rXhWAC2toYaAePZ68PGa5yaHqyBIQXdbZluRwa3Ukt_rQQSWLBFNnh9axD81QQxqd7FOd96AD9FRagQlNaSioy-fIBe-ikMOVUzJWtZE0z_UkudL-CG1udzzWyqjjmWgnLEUKaO_kHlYaF3Jtdd6_L-luDNliAzCX6mpZ5iVGffv22zr-6xK9BdWkXfTfPPj9vgi_vZu0vbn2LNANkAJvgYA7R3CEZqbgq1aQqVm0LdNIWaRfKByLh0U3n5jq77n_Q3nn0PSA
CitedBy_id crossref_primary_10_1007_s12015_021_10323_7
crossref_primary_10_4252_wjsc_v16_i2_70
crossref_primary_10_1186_s12967_024_05294_5
crossref_primary_10_1093_stmcls_sxae058
crossref_primary_10_1097_MCC_0000000000000784
crossref_primary_10_29328_journal_jsctt_1001021
crossref_primary_10_1016_j_cryobiol_2024_104856
crossref_primary_10_3390_cells12121664
crossref_primary_10_1186_s13287_023_03385_6
crossref_primary_10_3390_antibiotics10070750
crossref_primary_10_3390_ijms222312842
crossref_primary_10_1016_j_bcp_2024_116547
crossref_primary_10_1111_febs_16154
crossref_primary_10_2139_ssrn_3961380
crossref_primary_10_1055_s_0040_1713422
crossref_primary_10_3389_fimmu_2020_591065
crossref_primary_10_3390_cells12162105
crossref_primary_10_1097_ALN_0000000000004083
crossref_primary_10_1016_j_eclinm_2021_101167
crossref_primary_10_3389_fbioe_2020_619980
crossref_primary_10_7554_eLife_75053
crossref_primary_10_3390_ijms21218270
crossref_primary_10_3389_fphar_2023_1067422
crossref_primary_10_1080_17476348_2021_1848555
crossref_primary_10_1186_s13287_023_03618_8
crossref_primary_10_3389_fimmu_2022_820685
crossref_primary_10_1164_rccm_202302_0297OC
Cites_doi 10.1164/rccm.201001-0010OC
10.1136/thoraxjnl-2011-201059
10.1152/ajplung.00180.2011
10.1097/ALN.0000000000002327
10.1080/14653240600855905
10.1097/ALN.0b013e3181ba3c11
10.4049/jimmunol.179.3.1855
10.1164/rccm.201206-0990OC
10.1002/jcb.22088
10.1007/s00109-009-0523-7
10.1002/jcb.23395
10.1371/journal.pone.0008013
10.1183/09031936.00153211
10.1186/cc12696
10.1016/j.ccc.2011.04.004
10.1002/cbin.10188
10.1136/thoraxjnl-2011-201176
10.1152/ajplung.00144.2011
10.1136/thoraxjnl-2015-206813
10.1097/SHK.0b013e3181d49457
10.1097/CCM.0b013e3181a385d3
10.1002/stem.1681
10.1016/S2213-2600(14)70291-7
10.1002/stem.2779
10.1016/S2213-2600(18)30418-1
10.1073/pnas.1432929100
10.1097/CCM.0b013e31817d1b59
10.1186/scrt68
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2020
DBID AAYXX
CITATION
NPM
ISR
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13287-020-01624-8
DatabaseName CrossRef
PubMed
Science (Gale In Context)
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


PubMed


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1757-6512
EndPage 11
ExternalDocumentID oai_doaj_org_article_dd72cc88eb7a44899c617e1dd9e90e46
PMC7071745
A618736040
32169108
10_1186_s13287_020_01624_8
Genre Journal Article
GeographicLocations United Kingdom
United Kingdom--UK
Ireland
GeographicLocations_xml – name: United Kingdom
– name: Ireland
– name: United Kingdom--UK
GrantInformation_xml – fundername: European Research Council
  grantid: ERC-2007-StG 207777
– fundername: Health Research Board
  grantid: ILP-POR-2017-024
– fundername: Science Foundation Ireland
  grantid: 16/FRL/3845
– fundername: Health Research Board
  grantid: HRA-POR-2015-1099
– fundername: ;
  grantid: HRA-POR-2015-1099; ILP-POR-2017-024
– fundername: ;
  grantid: 16/FRL/3845
– fundername: ;
  grantid: ERC-2007-StG 207777
GroupedDBID ---
0R~
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFS
ACIHN
ACJQM
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ISR
ITC
KQ8
LK8
M1P
M7P
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SBL
SOJ
SV3
TUS
UKHRP
-56
-5G
-BR
3V.
ACRMQ
ADINQ
C24
NPM
PMFND
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c628t-c43836ad8ffc48a7397c2fa471dbdeb55cf9e246fe41e93122ab0febec0254783
IEDL.DBID 7X7
ISSN 1757-6512
IngestDate Wed Aug 27 01:32:29 EDT 2025
Thu Aug 21 14:10:24 EDT 2025
Fri Jul 11 01:03:49 EDT 2025
Fri Jul 25 12:10:40 EDT 2025
Tue Jun 17 21:02:09 EDT 2025
Tue Jun 10 20:32:59 EDT 2025
Fri Jun 27 03:45:24 EDT 2025
Thu May 22 21:21:40 EDT 2025
Thu Jan 02 23:00:06 EST 2025
Tue Jul 01 00:43:24 EDT 2025
Thu Apr 24 23:11:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Mesenchymal stem cell
Pneumonia
Antibiotics
Passage
Cryopreservation
ARDS
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c628t-c43836ad8ffc48a7397c2fa471dbdeb55cf9e246fe41e93122ab0febec0254783
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2378989213?pq-origsite=%requestingapplication%
PMID 32169108
PQID 2378989213
PQPubID 2040189
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_dd72cc88eb7a44899c617e1dd9e90e46
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7071745
proquest_miscellaneous_2377339837
proquest_journals_2378989213
gale_infotracmisc_A618736040
gale_infotracacademiconefile_A618736040
gale_incontextgauss_ISR_A618736040
gale_healthsolutions_A618736040
pubmed_primary_32169108
crossref_primary_10_1186_s13287_020_01624_8
crossref_citationtrail_10_1186_s13287_020_01624_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-03-13
PublicationDateYYYYMMDD 2020-03-13
PublicationDate_xml – month: 03
  year: 2020
  text: 2020-03-13
  day: 13
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Stem cell research & therapy
PublicationTitleAlternate Stem Cell Res Ther
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References M Mao (1624_CR4) 2010; 34
GF Curley (1624_CR11) 2012; 67
C.Y. Fong (1624_CR18) 2012; 113
Naveen Gupta (1624_CR27) 2012; 67
Jie Hua (1624_CR17) 2013; 38
JE Gotts (1624_CR1) 2011; 27
Donall F. O’Croinin (1624_CR21) 2008; 36
L Chimenti (1624_CR8) 2012; 40
Feng-Juan Lv (1624_CR25) 2014; 32
JG Wilson (1624_CR13) 2015; 3
K Nemeth (1624_CR7) 2010; 88
J Devaney (1624_CR12) 2015; 70
C Masterson (1624_CR16) 2018; 129
Shobha Mareddy (1624_CR24) 2009; 106
S Aguilar (1624_CR9) 2009; 4
MA Matthay (1624_CR14) 2019; 7
L Ionescu (1624_CR3) 2012; 303
LA Ortiz (1624_CR10) 2003; 100
Svitlana Danchuk (1624_CR26) 2011; 2
Jae W. Lee (1624_CR28) 2013; 187
J Costello (1624_CR23) 2009; 37
J Devaney (1624_CR20) 2013; 17
BD Higgins (1624_CR22) 2009; 111
M Dominici (1624_CR15) 2006; 8
N Gupta (1624_CR2) 2007; 179
S Mei (1624_CR5) 2010; 182
A Krasnodembskaya (1624_CR6) 2012; 302
SFH de Witte (1624_CR19) 2018; 36
References_xml – volume: 182
  start-page: 1047
  issue: 8
  year: 2010
  ident: 1624_CR5
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201001-0010OC
– volume: 67
  start-page: 496
  issue: 6
  year: 2012
  ident: 1624_CR11
  publication-title: Thorax.
  doi: 10.1136/thoraxjnl-2011-201059
– volume: 302
  start-page: L1003
  issue: 10
  year: 2012
  ident: 1624_CR6
  publication-title: Am J Physiol Lung Cell Mol Physiol
  doi: 10.1152/ajplung.00180.2011
– volume: 129
  start-page: 502
  issue: 3
  year: 2018
  ident: 1624_CR16
  publication-title: Anesthesiology.
  doi: 10.1097/ALN.0000000000002327
– volume: 8
  start-page: 315
  issue: 4
  year: 2006
  ident: 1624_CR15
  publication-title: Cytotherapy.
  doi: 10.1080/14653240600855905
– volume: 111
  start-page: 1317
  issue: 6
  year: 2009
  ident: 1624_CR22
  publication-title: Anesthesiology.
  doi: 10.1097/ALN.0b013e3181ba3c11
– volume: 179
  start-page: 1855
  issue: 3
  year: 2007
  ident: 1624_CR2
  publication-title: J Immunol
  doi: 10.4049/jimmunol.179.3.1855
– volume: 187
  start-page: 751
  issue: 7
  year: 2013
  ident: 1624_CR28
  publication-title: American Journal of Respiratory and Critical Care Medicine
  doi: 10.1164/rccm.201206-0990OC
– volume: 106
  start-page: 776
  issue: 5
  year: 2009
  ident: 1624_CR24
  publication-title: Journal of Cellular Biochemistry
  doi: 10.1002/jcb.22088
– volume: 88
  start-page: 5
  issue: 1
  year: 2010
  ident: 1624_CR7
  publication-title: J Mole Med
  doi: 10.1007/s00109-009-0523-7
– volume: 113
  start-page: 658
  issue: 2
  year: 2012
  ident: 1624_CR18
  publication-title: Journal of Cellular Biochemistry
  doi: 10.1002/jcb.23395
– volume: 4
  issue: 11
  year: 2009
  ident: 1624_CR9
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0008013
– volume: 40
  start-page: 939
  issue: 4
  year: 2012
  ident: 1624_CR8
  publication-title: Eur Respir J
  doi: 10.1183/09031936.00153211
– volume: 17
  start-page: R82
  issue: 2
  year: 2013
  ident: 1624_CR20
  publication-title: Crit Care
  doi: 10.1186/cc12696
– volume: 27
  start-page: 719
  issue: 3
  year: 2011
  ident: 1624_CR1
  publication-title: Crit Care Clin
  doi: 10.1016/j.ccc.2011.04.004
– volume: 38
  start-page: 198
  issue: 2
  year: 2013
  ident: 1624_CR17
  publication-title: Cell Biology International
  doi: 10.1002/cbin.10188
– volume: 67
  start-page: 533
  issue: 6
  year: 2012
  ident: 1624_CR27
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2011-201176
– volume: 303
  start-page: L967
  issue: 11
  year: 2012
  ident: 1624_CR3
  publication-title: Am J Physiol Lung Cell Mol Physiol
  doi: 10.1152/ajplung.00144.2011
– volume: 70
  start-page: 625
  issue: 7
  year: 2015
  ident: 1624_CR12
  publication-title: Thorax.
  doi: 10.1136/thoraxjnl-2015-206813
– volume: 34
  start-page: 196
  issue: 2
  year: 2010
  ident: 1624_CR4
  publication-title: Shock.
  doi: 10.1097/SHK.0b013e3181d49457
– volume: 37
  start-page: 2412
  issue: 8
  year: 2009
  ident: 1624_CR23
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e3181a385d3
– volume: 32
  start-page: 1408
  issue: 6
  year: 2014
  ident: 1624_CR25
  publication-title: STEM CELLS
  doi: 10.1002/stem.1681
– volume: 3
  start-page: 24
  issue: 1
  year: 2015
  ident: 1624_CR13
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(14)70291-7
– volume: 36
  start-page: 602
  issue: 4
  year: 2018
  ident: 1624_CR19
  publication-title: Stem Cells
  doi: 10.1002/stem.2779
– volume: 7
  start-page: 154
  issue: 2
  year: 2019
  ident: 1624_CR14
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(18)30418-1
– volume: 100
  start-page: 8407
  issue: 14
  year: 2003
  ident: 1624_CR10
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1432929100
– volume: 36
  start-page: 2128
  issue: 7
  year: 2008
  ident: 1624_CR21
  publication-title: Critical Care Medicine
  doi: 10.1097/CCM.0b013e31817d1b59
– volume: 2
  start-page: 27
  issue: 3
  year: 2011
  ident: 1624_CR26
  publication-title: Stem Cell Research & Therapy
  doi: 10.1186/scrt68
SSID ssj0000330064
Score 2.3525786
Snippet Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard approaches to...
Background Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However, standard...
Abstract Background Mesenchymal stromal cells (MSCs) demonstrate considerable promise for acute respiratory distress syndrome (ARDS) and sepsis. However,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 116
SubjectTerms Adult respiratory distress syndrome
Analysis
Antibiotics
ARDS
Bone marrow
Cell therapy
Cryopreservation
E coli
Escherichia coli
Infection
Isolation
Mesenchymal stem cell
Mesenchymal stem cells
Mesenchyme
Ostomy
Passage
Pneumonia
Production management
Respiratory distress syndrome
Setting (Literature)
Stem cells
Stromal cells
Time
Umbilical cord
Ventilators
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yIPgifls9NYrgw229NummiW_neccp6IO6cG8hzYe3cNsu211h_xP_XGfSbtki6IsPZaGZQHdmMh9h5jeEvFYiOLB7PvVOybTgIqTKmSy1UmSVUR5CeuxG_vxFXMyKT5fTy71RX1gT1sEDd4w7dq5k1krpq9JAKqGUBZ_rc-eUV5kvItg2-Ly9ZCraYEjTwdnuumSkOG4h7YLzhNkSRDmsSOXIE0XA_j_N8p5fGtdM7jmh8zvkdh890pPuq--SG76-R2528yS398mv2QJrXYHtFJPK1IF6_fSOnn4AB3JEF9hpZK-2C1hv16sGf_HivqUQudKzt7Dpek6Xtd-Abs7NO9q1UNImUNe0nuIQh4WvJ3QJETfYoQm1q22corK72Z1QUzt4sBGlgW-kXXvX9gGZnZ99P71I-9ELqRVMrlOLCKbCOBmCLaQpIWqxLBjwZK5yvppObVCeFSL4IveK54yZKguoENhdX0r-kBzUTe0fE2qFqqRlpuChKgLjVcas4ZB4M6DnyiQk34lB2x6XHMdjXOuYn0ihO9FpEJ2OotMyIUfDnmWHyvFX6vco3YESEbXjC9Az3euZ_peeJeQF6obu2lMHu6BPRC5LLsAWJuRVpEBUjRrLdn6YTdvqj9--joje9EShgX9pTd8FAbxCIK4R5eGIEo69HS_vlFT3ZqfVjJc4DpTlPCEvh2XciaV0tW82kabkXEleJuRRp9MDZzhD7KQMOFaOtH3EuvFKPb-KoOQlXgwU0yf_g9dPyS0WDypPc35IDtarjX8Gsd-6eh6P-W8wq1cT
  priority: 102
  providerName: Directory of Open Access Journals
Title Umbilical cord-derived CD362+ mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy
URI https://www.ncbi.nlm.nih.gov/pubmed/32169108
https://www.proquest.com/docview/2378989213
https://www.proquest.com/docview/2377339837
https://pubmed.ncbi.nlm.nih.gov/PMC7071745
https://doaj.org/article/dd72cc88eb7a44899c617e1dd9e90e46
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9Mw0IJNSLwgvgmMYhASD2tYYqeOzQtaR6eBxIQKlSpeLMd2tkprUpoWqf-En8tdkpZFSHtoKsVnKfF9X-6DkLdK5A7kng-9UzJMuMhD5UwUWimizCgPJj1WI389F2eT5Mt0MG0DblWbVrmVibWgdqXFGPkR4ylOOmQx_7j4FeLUKPy62o7QuE32sXUZpnSl03QXY4nAWQeVu62VkeKoAucLuAp9JrB1WBLKjj6q2_b_L5yvaadu5uQ1VXR6n9xrbUh63CD9Abnli4fkTjNVcvOI_JnMMeMVDp-iaxk6ILLf3tGTT6BGDukc643s5WYO69VqWeI_hu8rCvYrHb2HTVczuij8Gl55Zj7QppCSljl1ZeUpjnKY-6JPF2B3gzTqU7vc1LNUtvHdPjWFgx-Wo5TwjLQp8to8JpPT0Y-Ts7AdwBBaweQqtNjHVBgn89wm0qRgu1iWG9BnLnM-GwxsrjxLRO6T2CseM2ayKEeywBr7VPInZK8oC_-MUCtUJi0zCc-zJGc8i5g1HNxvBvBcmYDEWzRo23YnxyEZV7r2UqTQDeo0oE7XqNMyIIe7PYumN8eN0EPE7g4S-2rXN8rlhW7ZVDuXMmul9FlqwHFVyoKF52PnlFeRT0RAXiFt6KZIdScd9LGIZcoFSMSAvKkhsLdGgck7F2ZdVfrz93EH6F0LlJfwlta0tRBwVtiOqwN50IEE5rfd5S2R6lb4VPofqwTk9W4Zd2JCXeHLdQ2Tcq4kTwPytKHp3clwhh2UIjixtEPtnaPrrhSzy7o1eYrhgWTw_ObHekHuspoFeRjzA7K3Wq79S7DtVlmvZuAe2R-Ozr-Ne3WEBK7j4c-_sx9Rmg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELZKKwQviJtAoQaBeOiGJnY2sZEQ6qmWHkKlK_XNOLbTVuomy2YXtP-EX8FvZCbH0gipb31YrbQer2LP-JsZZw5C3so4s4B7zndWCj_iceZLqwPfiDhItXRg0mM28uFRvDuIvpz2TxfInzYXBsMqW0ysgNoWBu_I1xhPsNMhC_nn0Q8fu0bh29W2hUYtFvtu9gtctvLT3hbw9x1jO9snm7t-01XANzETE99gcc5YW5FlJhI6AYVsWKYBpG1qXdrvm0w6FsWZi0IneciYToMM14qJ44ng8L-3yBIsKwAgWNrYPvp6PL_VCThHJd9m54h4rQR3D84xemlgXbHIFx0NWDUK-F8dXNGH3VjNK8pv5z6511itdL0WswdkweUPye26j-XsEfk9GGKMLbCbojPrWxDrn87SzS1QXKt0iBlO5nw2hPFyMi7wG18YlBQsZrr9ASZdXtBR7qawyRf6I61TN2mRUVuUjmLziKHLe3QElj7gX4-a8azq3tLeKPeozi18MAGmgGekdVrZ7DEZ3AhznpDFvMjdM0JNLFNhmI54lkYZ42nAjObg8DOg51J7JGzZoExTDx3bclyqyi8SsapZp4B1qmKdEh5Znc8Z1dVArqXeQO7OKbGSd_VDMT5TDTAoaxNmjBAuTTS4ylIasCldaK10MnBR7JEVlA1Vp8XO8Uitx6FIQAajwCNvKgqs5pFjuNCZnpal2vt23CF63xBlBazS6Cb7AvYKC4B1KJc7lAA3pjvcCqlq4K5U_w6nR17Ph3EmhvDlrphWNAnnUvDEI09rmZ7vDGdYsymAHUs60t7Zuu5IfnFeFUNP8EIi6j-__rFWyJ3dk8MDdbB3tP-C3GXVceR-yJfJ4mQ8dS_Bspykr5rjTMn3m0aQvx06jZc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Umbilical+cord-derived+CD362%2B+mesenchymal+stromal+cells+for+E.+coli+pneumonia%3A+impact+of+dose+regimen%2C+passage%2C+cryopreservation%2C+and+antibiotic+therapy&rft.jtitle=Stem+cell+research+%26+therapy&rft.au=Masterson%2C+Claire&rft.au=Horie%2C+Shahd&rft.au=Loftus%2C+Paul&rft.au=O%27Brien%2C+Timothy&rft.date=2020-03-13&rft.pub=BioMed+Central+Ltd&rft.issn=1757-6512&rft.eissn=1757-6512&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1186%2Fs13287-020-01624-8&rft.externalDBID=n%2Fa&rft.externalDocID=A618736040
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-6512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-6512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-6512&client=summon